Literature DB >> 19830726

Reassessing the role of HLA-DRB3 T-cell responses: evidence for significant expression and complementary antigen presentation.

Rosa Faner1, Eddie James, Laurie Huston, Ricardo Pujol-Borrel, William W Kwok, Manel Juan.   

Abstract

In humans, several HLA-DRB loci (DRB1/3/4/5) encode diverse beta-chains that pair with alpha-chains to form DR molecules on the surface of APC. While DRB1 and DRB5 have been extensively studied, the role of DRB3/4 products of DR52/DR53 haplotypes has been largely neglected. To clarify the relative expression of DRB3, we quantified DRB3 mRNA levels in comparison with DRB1 mRNA from the same haplotype in both B cells and monocytes, observing quantitatively significant DRB3 synthesis. In CD19+ cells, DRB1*03/11/13 was 3.5-fold more abundant than DRB3, but in CD14+ this difference was only two-fold. Monocytes also had lower overall levels of DR mRNA compared with B cells, which was confirmed by cell surface staining of DRB1 and DRB3. To evaluate the functional role of DRB3, tetramer-guided epitope mapping was used to detect T cells against tetanus toxin and several influenza antigens presented by DRB3*0101/0202 or DRB1*03/11/13. None of the epitopes discovered were shared among any of the DR molecules. Quantitative assessment of DRB3-tetanus toxin specific T cells revealed that they are present at similar frequencies as those observed for DRB1. These results suggest that DRB3 plays a significant role in antigen presentation with different epitopic preferences to DRB1. Therefore, DRB3, like DRB5, serves to extend and complement the peptide repertoire of DRB1 in antigen presentation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19830726      PMCID: PMC2830809          DOI: 10.1002/eji.200939225

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  53 in total

1.  Immunochemical analysis of a cell transfected with an HLA-DR gene reveals a new alloantigenic specificity within HLA-DRw52.

Authors:  R Tosi; N Tanigaki; C De Préval; J Gorski; B Mach
Journal:  Eur J Immunol       Date:  1986-12       Impact factor: 5.532

2.  mRNA abundance, rather than differences in subunit assembly, determine differential expression of HLA-DR beta 1 and -DR beta 3 molecules.

Authors:  T Cotner; H Charbonneau; E Mellins; D Pious
Journal:  J Biol Chem       Date:  1989-07-05       Impact factor: 5.157

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  Delineation of several DR-restricted tetanus toxin T cell epitopes.

Authors:  S Demotz; A Lanzavecchia; U Eisel; H Niemann; C Widmann; G Corradin
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

5.  HLA-DR2a is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals.

Authors:  D Jaraquemada; R Martin; S Rosen-Bronson; M Flerlage; H F McFarland; E O Long
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

6.  HLA-DRB1 and -DRB4 genes are differentially regulated at the transcriptional level.

Authors:  L L Stunz; R W Karr; R A Anderson
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

7.  Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors.

Authors:  M Pette; K Fujita; D Wilkinson; D M Altmann; J Trowsdale; G Giegerich; A Hinkkanen; J T Epplen; L Kappos; H Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

8.  Major histocompatibility complex class II-restricted antigen presentation across a species barrier: conservation of restriction determinants in evolution.

Authors:  R E Bontrop; D G Elferink; N Otting; M Jonker; R R de Vries
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

9.  Functional polymorphism of each of the two HLA-DR beta chain loci demonstrated with antigen-specific DR3- and DRw52-restricted T cell clones.

Authors:  C Irlé; D Jaques; J M Tiercy; S V Fuggle; J Gorski; A Termijtelen; M Jeannet; B Mach
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

10.  Analysis of HLA-DR glycoproteins by DNA-mediated gene transfer. Definition of DR2 beta gene products and antigen presentation to T cell clones from leprosy patients.

Authors:  D Wilkinson; R R de Vries; J A Madrigal; C B Lock; J P Morgenstern; J Trowsdale; D M Altmann
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

View more
  10 in total

1.  Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.

Authors:  Maha Ayyoub; Danijel Dojcinovic; Pascale Pignon; Isabelle Raimbaud; Julien Schmidt; Immanuel Luescher; Danila Valmori
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

2.  Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis.

Authors:  Johannes R Hov; Vasilis Kosmoliaptsis; James A Traherne; Marita Olsson; Kirsten M Boberg; Annika Bergquist; Erik Schrumpf; J Andrew Bradley; Craig J Taylor; Benedicte A Lie; John Trowsdale; Tom H Karlsen
Journal:  Hepatology       Date:  2011-05-13       Impact factor: 17.425

3.  DRB4*01:01 Has a Distinct Motif and Presents a Proinsulin Epitope That Is Recognized in Subjects with Type 1 Diabetes.

Authors:  Eddie A James; Laurel Gillette; Ivana Durinovic-Bello; Cate Speake; George P Bondinas; Antonis K Moustakas; Carla J Greenbaum; George K Papadopoulos; William W Kwok
Journal:  J Immunol       Date:  2018-11-19       Impact factor: 5.422

4.  Immunodominant CD4+ T-cell responses to influenza A virus in healthy individuals focus on matrix 1 and nucleoprotein.

Authors:  Li Chen; Damien Zanker; Kun Xiao; Chao Wu; Quanming Zou; Weisan Chen
Journal:  J Virol       Date:  2014-07-30       Impact factor: 5.103

5.  Comparing HLA shared epitopes in French Caucasian patients with scleroderma.

Authors:  Doua F Azzouz; Justyna M Rak; Isabelle Fajardy; Yannick Allanore; Kiet Phong Tiev; Dominique Farge-Bancel; Marielle Martin; Sami B Kanaan; Philippe P Pagni; Eric Hachulla; Jean Robert Harlé; Rémi Didelot; Brigitte Granel; Jean Cabane; Jean Roudier; Nathalie C Lambert
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

6.  The prevalence of antibodies against the HLA-DRB3 protein in kidney transplantation and the correlation with HLA expression.

Authors:  Thomas H P M Habets; Bouke G Hepkema; Niels Kouprie; Melanie C A Schnijderberg; Tim C van Smaalen; Laura B Bungener; Maarten H L Christiaans; Gerard M J Bos; Joris Vanderlocht
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

7.  Accurate MHC Motif Deconvolution of Immunopeptidomics Data Reveals a Significant Contribution of DRB3, 4 and 5 to the Total DR Immunopeptidome.

Authors:  Saghar Kaabinejadian; Carolina Barra; Bruno Alvarez; Hooman Yari; William H Hildebrand; Morten Nielsen
Journal:  Front Immunol       Date:  2022-01-26       Impact factor: 7.561

Review 8.  Approaching Genetics Through the MHC Lens: Tools and Methods for HLA Research.

Authors:  Venceslas Douillard; Erick C Castelli; Steven J Mack; Jill A Hollenbach; Pierre-Antoine Gourraud; Nicolas Vince; Sophie Limou
Journal:  Front Genet       Date:  2021-12-02       Impact factor: 4.599

9.  Unique Molecular Identifier-Based High-Resolution HLA Typing and Transcript Quantitation Using Long-Read Sequencing.

Authors:  Caleb Cornaby; Maureen C Montgomery; Chang Liu; Eric T Weimer
Journal:  Front Genet       Date:  2022-06-13       Impact factor: 4.772

10.  The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity.

Authors:  Daphné Laubreton; Sylvie Bay; Christine Sedlik; Cécile Artaud; Christelle Ganneau; Edith Dériaud; Sophie Viel; Anne-Laure Puaux; Sebastian Amigorena; Catherine Gérard; Richard Lo-Man; Claude Leclerc
Journal:  Cancer Immunol Immunother       Date:  2016-02-04       Impact factor: 6.968

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.